Aevi Genomic Medicine Inc
GNMX
GNMX was delisted on the 3rd of February, 2020.
29 hedge funds and large institutions have $752K invested in Aevi Genomic Medicine Inc in 2019 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 4 increasing their positions, 7 reducing their positions, and 3 closing their positions.
33% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 3
4% more funds holding
Funds holding: 28 → 29 (+1)
6% less capital invested
Capital invested by funds: $803K → $752K (-$51K)
43% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$175K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$115K |
| 3 |
AMCA
Arthur M. Cohen & Associates
Northbrook,
Illinois
|
+$13K |
| 4 |
TSS
Two Sigma Securities
New York
|
+$7.84K |
| 5 |
OIA
OneDigital Investment Advisors
Overland Park,
Kansas
|
+$3.15K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VF
Virtu Financial
New York
|
-$46.9K |
| 2 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$44K |
| 3 |
Acadian Asset Management
Boston,
Massachusetts
|
-$35.3K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$25K |
| 5 |
BlackRock
New York
|
-$19.6K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Morgan Stanley
New York
| – | -$25 | -123 | -3% |
|
GNMX Hedge Fund Activity: Q2 2019 in Review
29 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in Aevi Genomic Medicine Inc (GNMX) for Q2 2019, worth a combined $752K — down 6.4% from $803K a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new GNMX positions and 3 closed out — a net gain of 1 holder — while 4 added to existing stakes and 7 trimmed.
The largest buyer was Renaissance Technologies, adding an estimated $175K. The largest seller was Virtu Financial, cutting an estimated $46.9K.
- 29 institutional investors held Aevi Genomic Medicine Inc (GNMX) as of Q2 2019, up from 28 in Q1 2019.
- Funds reported $752K of Aevi Genomic Medicine Inc stock for Q2 2019, down 6.4% quarter-over-quarter.
- 4 funds opened new Aevi Genomic Medicine Inc positions in Q2 2019 and 3 closed out, a net change of +1 holder.
- The largest Aevi Genomic Medicine Inc buyer in Q2 2019 was Renaissance Technologies, an estimated $175K added.
- The largest Aevi Genomic Medicine Inc seller in Q2 2019 was Virtu Financial, an estimated $46.9K sold.
Based on aggregated 13F filings for Q2 2019.